Compare CHEF & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHEF | HRMY |
|---|---|---|
| Founded | 1985 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 1.7B |
| IPO Year | 2011 | 2020 |
| Metric | CHEF | HRMY |
|---|---|---|
| Price | $64.33 | $27.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $76.83 | $46.70 |
| AVG Volume (30 Days) | 424.4K | ★ 1.1M |
| Earning Date | 05-12-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.27 | 7.97 |
| EPS | 1.68 | ★ 2.71 |
| Revenue | ★ $1,301,520,000.00 | $868,453,000.00 |
| Revenue This Year | $8.88 | $19.87 |
| Revenue Next Year | $7.64 | $12.49 |
| P/E Ratio | $38.08 | ★ $10.23 |
| Revenue Growth | 9.11 | ★ 21.51 |
| 52 Week Low | $45.00 | $25.52 |
| 52 Week High | $73.94 | $40.87 |
| Indicator | CHEF | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 45.83 | 29.93 |
| Support Level | $60.76 | $25.71 |
| Resistance Level | $65.47 | $30.96 |
| Average True Range (ATR) | 2.40 | 1.12 |
| MACD | -0.54 | 0.08 |
| Stochastic Oscillator | 35.43 | 47.95 |
The Chefs' Warehouse Inc is a specialty food distributor in metropolitan areas across the United States and Canada. The company's product portfolio is comprised of imported and local specialty food products such as cheese, cooking oils, chocolates, dried food, baking products, meats, and other food products. It operates via one reporting segment called Food Product Distribution. Operations are concentrated on the east, midwest, and west coasts of the U.S. The company provides service to restaurants, clubs, hotels, caterers, schools, bakeries, casinos, and specialty food stores.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.